Amarin Corp Plc (AMRN)

[Whalatane]

Ram. I agree that we are very unlikely to see another EPA trial the size and length of R-IT .
A trial of a high risk sub group ...say 2,000 PCI patients followed for 3 yrs for rate of re vascularization ? What's the patent life in the EU now with the new extension ?
If thats what it takes to get reimbursement in Germany and France it might be worth it . At least more / larger RWE studies.

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039

Kiwi